Investing.com -- AbbVie (NYSE:ABBV) saw its shares jump more than 4% in premarket trading Friday after the company's profit guidance for the fiscal 2025 year exceeded analyst expectations, driven by strong sales in immunology drugs Skyrizi and Rinvoq.
The pharmaceutical company reported Q4 earnings per share (Q4) of $2.16, topping consensus estimates of $2.06. Revenue came in at $15.1 billion, also above the consensus projection of $14.82 billion.
Sales of Humira declined 49% year-over-year to $1.68 billion, falling short of analyst expectations of $1.99 billion, according to LSEG data. However, the decline was offset by Skyrizi, which generated $3.78 billion in revenue, ahead of the $3.57 billion estimate, and Rinvoq sales, which stood at $1.83 billion, exceeding the projected $1.71 billion.
Adjusted research and development expenses rose 18% year-over-year to $2.27 billion, above the $2.07 billion consensus forecast.
"2024 was a year of significant progress for AbbVie. Our growth platform delivered outstanding results, we advanced our pipeline with key regulatory approvals and promising data, and we strengthened our business through strategic transactions," said Robert A. Michael, CEO of AbbVie.
"We are entering 2025 with significant momentum and expect net revenues to exceed their previous peak in just the second full year following the U.S. Humira loss of exclusivity."
For full-year 2025, AbbVie expects earnings per share between $12.12 and $12.32, compared to the consensus estimate of $12.13.